CAR-T cell therapy in neuro-oncology: applications and toxicity  

作　　者：Akanksha Sharma Gustavo De Leon Alyx Porter Marie F Grill Allison Rosenthal Christine E Brown Kristin Swanson Maciej M Mrugala 

机构地区：[1]Department of Neurology,Mayo Clinic,Phoenix,AZ 85054,USA [2]Division of Hematology-Oncology,Mayo Clinic,Phoenix,AZ 85054,USA [3]Mathematical Neuro-Oncology Lab,Mayo Clinic,Phoenix,AZ 85054,USA [4]Department of Hematology and Hematopoietic Cell Transplantation,T Cell Therapeutics Research Laboratory,City of Hope Beckman Research Institute,Duarte,CA 91010,USA.

出　　处：《Neuroimmunology and Neuroinflammation》2018年第10期15-26,共12页神经免疫与神经炎症（英文版）

摘　　要：A new era for cancer treatment has been ushered in with the field of cancer immunotherapy. After initial success with systemic malignancies, several of these promising treatments are being investigated for efficacy with primary and secondary brain tumors. Chimeric antigen receptor (CAR) T cells are being studied, both with systemic infusion and direct administration to the tumor and into the cerebrospinal fluid, with promising early results. Systemic CAR-T treatment can have serious systemic and neurological toxicities that are important for the practicing neurologist and neuro-oncologist to know and understand. This review aims to discuss adoptive cell therapies with a focus on CAR-T treatment. We review use of this therapy in brain cancers, particularly malignant glioma, and provide an overview of the toxicity of CAR-T treatment and its appropriate management.

关 键 词：CAR-T cell IMMUNOTHERAPY brain tumor CYTOKINE release SYNDROME 

分 类 号：R73[医药卫生—肿瘤]